Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7D4 | ISIN: CA05156V1022 | Ticker-Symbol: IKAP
Tradegate
06.06.25 | 11:32
7,042 Euro
-0,37 % -0,026
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
AURINIA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AURINIA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,2527,32615:54
7,2527,32615:54

Aktuelle News zur AURINIA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.05.Aurinia Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans10
12.05.Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance10
12.05.Aurinia outlines $250M-$260M 2025 revenue target as LUPKYNIS sales climb 25% and operational efficiency improves3
12.05.Leerink maintains Aurinia stock Outperform with $10 target5
12.05.Aurinia Pharma GAAP EPS of $0.16 beats by $0.06, revenue of $62.47M beats by $1.41M4
AURINIA PHARMACEUTICALS Aktie jetzt für 0€ handeln
12.05.Aurinia Pharmaceuticals Inc. - 10-Q, Quarterly Report3
12.05.Aurinia Pharmaceuticals Inc. - 8-K, Current Report4
09.05.Aurinia Pharma Q1 2025 Earnings Preview4
09.05.Uncovering Potential: Aurinia Pharmaceuticals' Earnings Preview8
05.03.Aurinia Pharmaceuticals stock climbs on insider buying8
27.02.Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations7
27.02.Aurinia Pharma reports mixed Q4 results; initiates FY25 outlook16
27.02.Aurinia Pharmaceuticals Inc. - 10-K, Annual Report3
27.02.Aurinia Pharmaceuticals Inc. - 8-K, Current Report1
07.11.24Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development228ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months...
► Artikel lesen
13.08.24On behalf of Lucien Selce: Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board455Highlights Damning Annual General Meeting Results, Which Show That Four of the Company's Nine Directors Failed to Receive a Majority of the Votes Calls on the Company to Appoint Two Shareholder...
► Artikel lesen
01.08.24Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results226ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the second quarter and six months...
► Artikel lesen
07.06.24ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal619SEOUL, South Korea, June 7, 2024 /PRNewswire/ -- Dear Fellow Shareholders, ILJIN SNT Co., Ltd. ("ILJIN") is a long-standing investor of Aurinia Pharmaceuticals Inc. ("Aurinia" or...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1